Search





Search





Markets
/
Stocks
/
nasdaq-mgx
/

Metagenomi Inc

MGX

Add to Watchlist

1.310USD

-0.040-2.96%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

49.32MMarket Cap

LossP/E TTM



Metagenomi Inc

1.310

-0.040-2.96%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Metagenomi Inc

Currency: USD Updated: 2026-05-15

Key Insights

Metagenomi Inc's fundamentals are relatively healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 100 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.33.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Metagenomi Inc's Score

Industry at a Glance

Industry Ranking

100 / 382

Overall Ranking

222 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Metagenomi Inc Highlights

StrengthsRisks

Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.

Growing

The company is in a growing phase, with the latest annual income totaling USD 25.21M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 25.21M.

Overvalued

The company’s latest PE is -0.57, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 8.82M shares, decreasing 42.09% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 628.40K shares of this stock.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

8.333

Target Price

+517.28%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Metagenomi Inc is 8.45, ranking 34 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 1.25M, representing a year-over-year decrease of 69.76%, while its net profit experienced a year-over-year decrease of 7.91%.

Score

Industry at a Glance

Previous score

8.45

Change



Financials

6.41

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.25

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.60

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Metagenomi Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Metagenomi Inc is 9.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.57, which is -7.29% below the recent high of -0.53 and -1080.37% above the recent low of -6.74.

Score

Industry at a Glance

Previous score

9.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 100/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Metagenomi Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 12.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

8.333

Target Price

+517.28%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Metagenomi Inc

MGX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Metagenomi Inc is 4.59, ranking 340 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.47 and the support level at 1.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.77

Change

-0.18

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.019

Sell

RSI(14)

37.861

Neutral

STOCH(KDJ)(9,3,3)

22.494

Sell

ATR(14)

0.065

High Vlolatility

CCI(14)

-136.252

Sell

Williams %R

94.444

Oversold

TRIX(12,20)

-0.173

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.348

Sell

MA10

1.382

Sell

MA20

1.415

Sell

MA50

1.427

Sell

MA100

1.516

Sell

MA200

1.818

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Metagenomi Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 23.43%, representing a quarter-over-quarter increase of 31.16%. The largest institutional shareholder is James Simons, holding a total of 787.90K shares, representing 2.09% of shares outstanding, with 685.62% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Bayer HealthCare LLC

4.05M

Thomas (Brian C)

2.36M

-0.16%

Two Sigma Investments, LP

654.39K

+142.26%

Renaissance Technologies LLC

Star Investors

628.40K

+276.29%

Irish (Jian)

594.26K

-0.27%

Sozo Ventures LLC

581.58K

Catalio Capital Management, LP

528.99K

Peapod Lane Capital LLC

497.65K

-3.15%

Bridgeway Capital Management, LLC

395.80K

+102.15%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Metagenomi Inc is 2.10, ranking 241 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Metagenomi Inc’s latest ESG disclosure is at an average level in the Biotechnology & Medical Research industry, showing no material impact on overall risk.